Current State Of Proton And Carbon-Ion Radiotherapy At The Hyogo Ion Beam Medical Center (HIBMC)

Journal Article · Wed Jun 01 00:00:00 EDT 2011 · AIP Conference Proceedings

DOI:https://doi.org/10.1063/1.3586123· OSTI ID:21519892

Murakami, Masao; Hishikawa, Yoshio ^[1]; Demizu, Yusuke; Niwa, Yasue; Fujii, Osamu; Terashima, Kazuki; Mima, Masayuki; Miyawaki, Daisuke; Sasaki, Ryohei; Abe, Mitsuyuki ^[2]

---

1. Department of Radiology, Hyogo Ion Beam Medical Center (HIBMC), Division of Ion Beam Therapy, Kobe University Graduate School of Medicine (Japan)
2. Department of Radiology, Hyogo Ion Beam Medical Center (HIBMC) (Japan)

HIBMC is the world's first facility to be able to use both proton (PRT) and carbon-ion radiotherapy (CiRT). The medically dedicated synchrotron can accelerate protons up to 230 MeV and carbon ions up to 320 MeV. From April 2001 to March 2010, the facility treated 3275 patients, with 2487 patients treated using PRT and 788 using CiRT. Particle radiotherapy was delivered to patients suffering from malignant tumors originating in the head and neck (502 patients), lungs (330), liver (539), prostate (1283), and the bone and soft tissue (130). The clinical results are as follows: (1) H and N tumors: The 2-year overall survival (OS) rates of patients with olfactory neuroblastoma, mucoepidermoid cancer, adenoid cystic cancer, adenocarcinoma, squamous cell carcinoma, and malignant melanoma was 100%, 86%, 78%, 78%, 66%, and 62%, respectively. (2) Lung cancer: For all 80 patients, the 3-year OS rate was 75%(Stage IA: 74%; Stage IB: 76%) and local control (LC) rate was 82%(IA: 87%; IB: 77%). Grade 3 pulmonary toxicity was observed in only 1 patient. These results are comparable to those obtained by surgery, and indicate proton therapy and carbon-ion therapy are safe and effective for stage I lung cancer. (3) Liver cancer: The 5-year LC rate for 429 tumor patient was 90%, and the 5-year OS rate for 364 patients was 38%. These results seem equivalent to those obtained by surgery or radio-frequency ablation. (4) Prostate cancer: In 290 patients treated by proton radiotherapy, five patients died from other disease in the median follow-up period of 62 months. Biochemical disease-free survival and OS rate at 5 years was 88.2% and 96.5%, respectively. Our proton radiotherapy showed excellent OS and biochemical disease-free survival rates with minimum late morbidities. PRT VS CiRT: From our retrospective analysis, it seems that there is no significant difference in the LC and OS rate in H and N, lung and liver cancer between PRT and CiRT.

• OSTI ID: 21519892
• Journal Information: AIP Conference Proceedings, Vol. 1336, Issue 1; Conference: CAARI 2010: 21. International Conference on the Application of Accelerators in Research and Industry, Fort Worth, TX (United States), 8-13 Aug 2010; Other Information: DOI: 10.1063/1.3586123; (c) 2011 American Institute of Physics; ISSN 0094-243X
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
43 PARTICLE ACCELERATORS
CARBON IONS
DISEASE INCIDENCE
DOSIMETRY
ION BEAMS
LIVER
LUNGS
MELANOMAS
MEV RANGE 100-1000
NECK
PATIENTS
PROSTATE
PROTONS
RADIOTHERAPY
RADIOWAVE RADIATION
SKELETON
SURGERY
SYNCHROTRON RADIATION
SYNCHROTRONS
TOXICITY
ACCELERATORS
BARYONS
BEAMS
BODY
BREMSSTRAHLUNG
CARCINOMAS
CHARGED PARTICLES
CYCLIC ACCELERATORS
DIGESTIVE SYSTEM
DISEASES
ELECTROMAGNETIC RADIATION
ELEMENTARY PARTICLES
ENERGY RANGE
EPITHELIOMAS
FERMIONS
GLANDS
HADRONS
IONS
MALE GENITALS
MEDICINE
MEV RANGE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEONS
ORGANS
RADIATIONS
RADIOLOGY
RESPIRATORY SYSTEM
THERAPY